Ignite Creation Date:
2025-12-25 @ 2:24 AM
Ignite Modification Date:
2025-12-27 @ 8:48 AM
Study NCT ID:
NCT04976634
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-04-06
First Post:
2021-07-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-08-18
Start Date Type:
ACTUAL
Primary Completion Date:
2027-03-22
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-03-22
Completion Date Type:
ESTIMATED
First Submit Date:
2021-07-16
First Submit QC Date:
None
Study First Post Date:
2021-07-26
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-04-03
Last Update Post Date:
2025-04-06
Last Update Post Date Type:
ACTUAL